| Status | In progress |
| Process | STA 2018 |
| ID number | 1372 |
Provisional Schedule
| Expected publication | 14 October 2020 |
Project Team
| Project lead | Gemma Barnacle |
Email enquiries
- If you have any queries please email TaCommF@nice.org.uk
| Evidence Review Group / Assessment Group | Centre for Reviews and Dissemination and Centre for Health Economics, University of York |
Consultees
| Companies sponsors | Eli Lilly (galcanezumab) |
| Others | Department of Health and Social Care |
| NHS Central Manchester CCG | |
| NHS England | |
| NHS Wakefield CCG | |
| Welsh Government | |
| Patient carer groups | Action on Pain |
| Brain and Spine Foundation | |
| Migraine Trust | |
| Muslim Council of Britain | |
| National Migraine Centre | |
| Neurological Alliance | |
| OUCH UK | |
| Pain Concern | |
| Pain Relief Foundation | |
| Pain UK | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| The Brain Charity | |
| Professional groups | Association of British Neurologists |
| British Association for the Study of Headache | |
| British Geriatrics Society | |
| British Neuropathological Society | |
| British Pain Society | |
| Institute of Neurology | |
| Migraine in Primary Care Advisors | |
| Neuromodulation Society of UK and Ireland | |
| Physiotherapy Pain Association | |
| Primary Care and Community Neurology Society | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| UK Clinical Pharmacy Association |
Commentators
| Associated public health groups | Public Health England |
| Public Health Wales | |
| Comparator companies | Accord (amitriptyline, propranolol, topiramate) |
| Allergan (botulinum toxin type A) | |
| Aurobindo Pharma-Milpharm (topiramate) | |
| Brown & Burk UK (amitriptyline) | |
| Glenmark Pharmaceuticals (topiramate) | |
| Janssen-Cilag (topiramate) | |
| Novartis (erenumab) | |
| Rosemont Pharmaceuticals (amitriptyline, propranolol, topiramate) | |
| Sandoz (propranolol) | |
| Teva (fremanezumab) | |
| Thame Laboratories (amitriptyline, propranolol) | |
| Wockhardt (amitriptyline) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| Allied Health Professionals Federation | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| Neurological Alliance of Scotland | |
| NHS Alliance | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Wales Neurological Alliance | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Brain Research Trust |
| British Neurological Research Trust | |
| Cochrane Pain, Palliative Care and Supportive Care Group | |
| Genomics England | |
| MRC Clinical Trials Unit | |
| National Hospital for Neurology and Neurosurgery | |
| National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 November 2019 | Invitation to participate |
| 22 November 2019 | In progress, Referred 2 August 2019. |
| 10 September 2019 | The Department for Health and Social Care has asked us to carry out a Single Technology Appraisal of galcanezumab for preventing migraine. The appraisal is expected to start in approximately late November 2019 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early February 2020. These timings are based on a request from the company to reschedule the initial date set by NICE until after the anticipated marketing authorisation has been received, in order to facilitate a suitably comprehensive and robust evidence submission. |
| 28 January 2019 - 25 February 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance